On 12 Nov 2026 Aflac closed at $126.51, +16.5% this year; market cap $63.09bn, P/E 17.9.
Financials · Life & Health Insurance · NYSE · United States
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
| Market cap | $63.09bn |
| P/E (trailing) | 17.9 |
| EPS (TTM) | $7.07 |
| Beta | 0.55 |
| Dividend | $2.44 |
| Dividend yield | 1.93% |
| Ex-dividend date | 18 Nov 2026 |
| Latest report | 4 Nov 2026 |
| Next earnings | 3 Feb 2027 |
| YTD | +16.5% |
| 1Y | +12.7% |
| 3Y | +18.3% |
| 5Y | +20.0% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $17.44bn | $3.65bn | $2.56bn |
| 2024 | $19.13bn | $5.44bn | $2.71bn |
| 2023 | $18.84bn | $4.66bn | $3.19bn |
| 2022 | $19.15bn | $4.42bn | $3.88bn |
| 2021 | $22.11bn | $4.33bn | $5.05bn |
We publish no single base value for Aflac. Our valuation methods put it between $23.39 and $162.24 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.